The Role of GLP-1 in Satiety Perception in Humans

• Status: Withdrawn
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Scientists have discovered a number of hormones that control our feelings of hunger and fullness. One particular hormone, called GLP-1, has been associated with feelings of hunger and fullness. The overall purpose of this study is to look more closely at how GLP-1 changes these feelings and to observe how these hormones affect the brain's function. To do this, volunteers will be asked to come to the clinic for a screening visit, and 2 study visits. This is an outpatient study with a screening visit which will last about an hour and the two subsequent study visits for about 3 hours each. During the study, patients will receive a drug that blocks the effect of a hormone made in the gut. We will take a series of blood samples to measure hormones and use functional magnetic resonance imaging (MRI) to take pictures of the brain. Understanding the action of these hormones in the brain may eventually lead to new ways to help people avoid obesity or lose weight.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Collaborator: Fred Hutchinson Cancer Research Center

Criteria

Inclusion Criteria:

1. Male or female between 18-29 years of age

2. BMI between 18.5-24.9 kg/m2

3. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

1. Chronic health conditions, including diabetes and kidney disease.

2. Current dieting for weight loss or restrained eating

3. History of obesity, eating disorders, or weight loss surgery

4. Random blood glucose >140

5. Pregnancy or use of oral contraceptives

6. Current smoker

7. Recreational drug use or alcohol use of > 1 drink per day for females, > 2 per day for males

8. Food allergy or intolerance to study foods.

9. Medications known to alter appetite (e.g., amphetamines, atypical antipsychotics) or gastric emptying (e.g., metoclopromide)

10. Contraindications to MRI, such as implanted metal or claustrophobia.

11. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.